Ignite Creation Date:
2024-05-05 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00368160
Status:
COMPLETED
Last Update Posted:
2012-02-22
First Post:
2006-08-23
Brief Title:
Study of an Evening Dose of Eszopiclone on Next Day Driving Ability PsychomotorMemory Function in Healthy Volunteers
Sponsor:
Sumitomo Pharma America Inc
Organization:
Sumitomo Pharma America Inc
Study Overview
Official Title:
The Effects of a Single Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability and PsychomotorMemory Function in Healthy Volunteers Compared to Placebo
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Male and female healthy volunteers Patients must also possess a full current driving license for at least one year and be a regular car driver
Detailed Description:
The study is a single centre randomised double blind placebo controlled 2-way crossover design in a group of 32 healthy male and female volunteers The medications under investigation are eszopiclone and placebo Volunteers will receive the study medications and placebo on the evening of Day 2 of each treatment period Performance will be assessed on Day 3 of each treatment period Each treatment period will be separated by at least a 7-day washout period This study was previously posted by Sepracor Inc In October 2009 Sepracor Inc was acquired by Dainippon Sumitomo Pharma and in October 2010 Sepracor Incs name was changed to Sunovion Pharmaceuticals Inc
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None